Essential thrombocythaemia treated with recombinant interferon: 'real world' United Kingdom referral centre experience.

Autor: Desterro J; Department of Haematology, Guy's and St. Thomas' NHS Foundation Trust, London, UK.; Serviço de Hematologia, Instituto Português de Oncologia de Lisboa, Lisboa, Portugal., McLornan DP; Department of Haematology, Guy's and St. Thomas' NHS Foundation Trust, London, UK.; Comprehensive Cancer Centre, King's College, London, UK., Curto Garcia N; Department of Haematology, Guy's and St. Thomas' NHS Foundation Trust, London, UK.; Comprehensive Cancer Centre, King's College, London, UK., O'Sullivan J; Department of Haematology, Guy's and St. Thomas' NHS Foundation Trust, London, UK., Alimam S; Department of Haematology, Guy's and St. Thomas' NHS Foundation Trust, London, UK., Keohane C; Department of Haematology, Guy's and St. Thomas' NHS Foundation Trust, London, UK., Woodley C; Department of Haematology, Guy's and St. Thomas' NHS Foundation Trust, London, UK., Francis Y; Department of Haematology, Guy's and St. Thomas' NHS Foundation Trust, London, UK., Kordasti S; Department of Haematology, Guy's and St. Thomas' NHS Foundation Trust, London, UK.; Comprehensive Cancer Centre, King's College, London, UK., Radia DH; Department of Haematology, Guy's and St. Thomas' NHS Foundation Trust, London, UK., Harrison CN; Department of Haematology, Guy's and St. Thomas' NHS Foundation Trust, London, UK.; Comprehensive Cancer Centre, King's College, London, UK.
Jazyk: angličtina
Zdroj: British journal of haematology [Br J Haematol] 2019 Aug; Vol. 186 (4), pp. 561-564. Date of Electronic Publication: 2019 May 15.
DOI: 10.1111/bjh.15968
Abstrakt: Standard first-line therapy choice for essential thrombocythaemia (ET) requiring cytoreduction, supported by randomized trials, is low-dose aspirin with hydroxycarbamide, but the role of recombinant interferon-alfa (IFNα)-2a/2b and pegylated (PEG)-IFN-α-2a/2b is increasingly highlighted. Longer-term outcome data, however, remains somewhat scarce, particularly in the 'real world'. We hereby report on a large, well-annotated cohort of ET patients from a single referral centre undergoing therapy with either IFNα or (PEG)-IFN-α-2a/2b and demonstrate high rates of complete haematological responses, good tolerability and safety, low rates of thromboembolic events in compliant patients and confirm feasibility of long-term therapy in a significant proportion of patients.
(© 2019 British Society for Haematology and John Wiley & Sons Ltd.)
Databáze: MEDLINE
Externí odkaz: